Insulet Corp.
This article was originally published in Start Up
Executive Summary
Infusion pumps have been on the market for almost 20 years, but their cost and complexity have restricted their use to only 10% of insulin-dependent diabetics. Insulet Corp. hopes to penetrate further into the diabetes market with a credit-card sized disposable insulin pump that attaches to the body with an adhesive, and is controlled by a wireless remote unit.
You may also be interested in...
Device IPO Class of 2007 Making News, Some Returns
The merger of Accuray and TomoTherapy would combine two of the 11 medical device companies that went public in 2007, a class of companies that has produced mixed results.
The Wireless Age in Diabetes: Insulet Raises $50 Million
Insulet, developer of a fundamentally new insulin delivery system, just raised $50 million in its fifth venture round. This brings the total it's raised to date to more than $120 million, which sounds like a tremendous sum for a small device company founded just six years ago, but relative to the size of the opportunity it's really not. There are one million diabetic patients who need to inject insulin several times a day to manage their diabetes. For these patients, Insulet has brought insulin pumps into the age of iPods.
US FDA Offers Clarity On UV Filter Environmental Impact Statement, GRASE Implications
Federal law requiring agencies to weigh and document potential environmental impacts of major regulatory actions does not dictate what happens next. Neither does it provide federal agencies with authorities beyond their statutory purviews, FDA/CDER leadership says.